Literature DB >> 23314264

The role of viscosupplementation.

Jeremie M Axe1, Lynn Snyder-Mackler, Michael J Axe.   

Abstract

The treatment of early osteoarthritis in middle-aged athletes with intra-articular (IA) viscosupplementation using hyaluronic acid (HA) has been used since the late 1980s. Administration of IA HA has demonstrated anti-inflammatory, anabolic, and analgesic effects. Treatment of acute injuries such as anterior cruciate ligament reconstruction and full thickness chondral lesions have benefited with the addition of IA HA. Use of IA HA has also been shown to delay total knee arthroplasty. Although IA HA has shown significant benefits in the middle-aged athletes, it is not a ubiquitous treatment option. Success with corticosteroid injections can be used as a clinical marker for subsequent success with HA injections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23314264     DOI: 10.1097/JSA.0b013e3182673241

Source DB:  PubMed          Journal:  Sports Med Arthrosc Rev        ISSN: 1062-8592            Impact factor:   1.985


  10 in total

1.  Will a single periarticular lidocaine-corticosteroid injection improve the clinical efficacy of intraarticular hyaluronic acid treatment of symptomatic knee osteoarthritis?

Authors:  Cemil Ertürk; Mehmet Akif Altay; Nuray Altay; Ali Murat Kalender; İbrahim Avşin Öztürk
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-11-02       Impact factor: 4.342

2.  Cochrane in CORR®: Viscosupplementation for the treatment of osteoarthritis of the knee.

Authors:  Nathan Evaniew; Nicole Simunovic; Jon Karlsson
Journal:  Clin Orthop Relat Res       Date:  2013-11-12       Impact factor: 4.176

3.  Oral intake of a liquid high-molecular-weight hyaluronan associated with relief of chronic pain and reduced use of pain medication: results of a randomized, placebo-controlled double-blind pilot study.

Authors:  Gitte S Jensen; Victoria L Attridge; Miki R Lenninger; Kathleen F Benson
Journal:  J Med Food       Date:  2015-01       Impact factor: 2.786

Review 4.  Temporomandibular joint osteoarthritis: diagnosis and long-term conservative management: a topic review.

Authors:  Mythili Kalladka; Samuel Quek; Gary Heir; Eli Eliav; Muralidhar Mupparapu; Archana Viswanath
Journal:  J Indian Prosthodont Soc       Date:  2013-09-22

5.  Comparison of Low-, Moderate-, and High-Molecular-Weight Hyaluronic Acid Injections in Delaying Time to Knee Surgery.

Authors:  Anand R Shewale; Charles L Barnes; Lori A Fischbach; Songthip T Ounpraseuth; Jacob T Painter; Bradley C Martin
Journal:  J Arthroplasty       Date:  2017-05-02       Impact factor: 4.757

Review 6.  Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis.

Authors:  Egemen Ayhan; Hayrettin Kesmezacar; Isik Akgun
Journal:  World J Orthop       Date:  2014-07-18

7.  The Viability and Anti-Inflammatory Effects of Hyaluronic Acid-Chitlac-Tracimolone Acetonide- β-Cyclodextrin Complex on Human Chondrocytes.

Authors:  Elena Tarricone; Rossella Elia; Elena Mattiuzzo; Alessia Faggian; Assunta Pozzuoli; Pietro Ruggieri; Paola Brun
Journal:  Cartilage       Date:  2020-02-28       Impact factor: 3.117

8.  Controlled Release of Interleukin-1 Receptor Antagonist from Hyaluronic Acid-Chitosan Microspheres Attenuates Interleukin-1β-Induced Inflammation and Apoptosis in Chondrocytes.

Authors:  Bo Qiu; Ming Gong; Qi-Ting He; Pang-Hu Zhou
Journal:  Biomed Res Int       Date:  2016-10-30       Impact factor: 3.411

Review 9.  Role of Intra-articular Platelet Rich Plasma in the Management of Osteoarthritis: A Review.

Authors:  Ujala Zubair; Osama Salam; Zarafshan Zubair
Journal:  Cureus       Date:  2018-09-25

10.  Anti-Inflammatory Performance of Lactose-Modified Chitosan and Hyaluronic Acid Mixtures in an In Vitro Macrophage-Mediated Inflammation Osteoarthritis Model.

Authors:  Elena Tarricone; Elena Mattiuzzo; Elisa Belluzzi; Rossella Elia; Andrea Benetti; Rina Venerando; Vincenzo Vindigni; Pietro Ruggieri; Paola Brun
Journal:  Cells       Date:  2020-05-26       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.